Brief: Calliditas Q2 Net Sales SEK 269.4 Million
17/08/2023 06:12
Aug 17 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* QTRLY NET SALES AMOUNTED TO SEK 269.4 MILLION
* LOSS PER SHARE BEFORE & AFTER DILUTION AMOUNTED TO SEK
1.71 AND
SEK 3.62 FOR THREE MONTHS ENDED JUNE, AND 2022, RESPECTIVELY
* HALF YEARLY NET SALES AMOUNTED TO SEK 460.7 MILLION
* LOSS PER SHARE BEFORE AND AFTER DILUTION AMOUNTED TO SEK
5.21
AND SEK 7.57 FOR SIX MONTHS ENDED JUNE AND 2022, RESPECTIVELY
Source text for Eikon: ID:nWkr997NTj
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations